Skip to content

20-206 - Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

Status: open

ACNS1422-A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Treatment for Pediatric Oncology - Medulloblastoma

Contact Us


To estimate the progression-free survival (PFS) of children ≥ 3 years of age with WNT-driven average-risk medulloblastoma using reduced craniospinal radiotherapy (CSI) (18 Gy) with a limited target volume boost to the tumor bed of 36 Gy for a total of 54 Gy and reduced chemotherapy approach (no vincristine during radiotherapy and reduced-dose maintenance chemotherapy) and to monitor the PFS for early evidence that the outcome is unacceptable.

Providers Associated With This Trial

Principle Investigator

Sub Investigators

This link will open in a new tab or window.